FDA Extends Roflumilast’s AD Approval to Young Children – Medscape

1. FDA Extends Roflumilast’s AD Approval to Young Children  Medscape
2. FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years  The American Journal of Managed Care® (AJMC®)
3. Arcutis Biotherapeutics Announces FDA Approval of ZORYVE® Cream 0.05% for Treatment of Atopic Dermatitis in Children Aged 2 to 5  Quiver Quantitative
4. Zoryve Cream 0.05% Approved for Atopic Dermatitis in 2- to 5-Year-Olds  Medical Professionals Reference
5. FDA Approves Roflumilast (Zoryve) Cream 0.05% for Atopic Dermatitis in Children Aged 2-5 Years  HCPLive

Continue Reading